The stirrings of a revolution are starting to ripple through hundreds of laboratories. It’s a revolution that aims to result in new medicines – faster and with fewer failures – and it’s being led by three UK universities and three global pharmaceutical companies.
Cambridge-based start-up company Bicycle Therapeutics has recently raised £40 million from a range of investors to bring its cancer drug candidates to clinical trials.
Improbable, founded by Cambridge alumni Herman Narula (Girton 2007) and Rob Whitehead (Robinson 2009), became the UK's latest $1billion tech startup this week.
A University of Cambridge spin-out company has raised £7 million in new funding, which will help in the development of treatments for liver and lung disease.
A new method for producing conductive cotton fabrics using graphene-based inks opens up new possibilities for flexible and wearable electronics, without the use of expensive and toxic processing steps.
A new treatment that might one day help all patients with haemophilia, including those that become resistant to existing therapies, has been developed by researchers at the University of Cambridge.
Cambridge spin-out Carrick Therapeutics raises $95 million in funding, representing the largest-ever early stage investment in a UK university spin-out company.
A smart material that switches back and forth between transparent and opaque could be installed in buildings or automobiles, potentially reducing energy bills by avoiding the need for costly air conditioning.
Researchers have built a nano-engine that could form the basis for future applications in nano-robotics, including robots small enough to enter living cells.